Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer (Q37335142)

19 August 2017

1 reference

title

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer (English)

1 reference

19 August 2017

1 reference

Quanri Jin

1

1 reference

19 August 2017

Francisco J Esteva

series ordinal

2

1 reference

19 August 2017

publication date

25 November 2008

1 reference

Journal of Mammary Gland Biology and Neoplasia

19 August 2017

published in

1 reference

19 August 2017

volume

13

1 reference

19 August 2017

issue

4

1 reference

19 August 2017

page(s)

485-498

1 reference

The insulin-like growth factor system and cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10911-008-9107-3

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-008-9107-3

Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-008-9107-3

A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-008-9107-3

Targeting multiple signal transduction pathways through inhibition of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-008-9107-3

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

12 December 2020

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

1 reference

12 December 2020

The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*

1 reference

12 December 2020

Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Use of trastuzumab for the treatment of early stage breast cancer

1 reference

12 December 2020

Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer

1 reference

12 December 2020

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

1 reference

12 December 2020

Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer

1 reference

12 December 2020

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

1 reference

12 December 2020

Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

1 reference

12 December 2020

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

1 reference

12 December 2020

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

1 reference

12 December 2020

Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

12 December 2020

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

1 reference

12 December 2020

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo

1 reference

12 December 2020

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells

1 reference

12 December 2020

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

1 reference

12 December 2020

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

1 reference

12 December 2020

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

12 December 2020

Trastuzumab: triumphs and tribulations

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells

1 reference

12 December 2020

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

12 December 2020

A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

1 reference

12 December 2020

Molecular portraits of human breast tumours

1 reference

12 December 2020

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

12 December 2020

Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway

1 reference

12 December 2020

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

12 December 2020

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

12 December 2020

Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

1 reference

12 December 2020

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

12 December 2020

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

1 reference

12 December 2020

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Clinical trials of Herceptin(R) (trastuzumab)

1 reference

12 December 2020

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

1 reference

12 December 2020

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

12 December 2020

Targeted therapy: wave of the future.

1 reference

12 December 2020

Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes

1 reference

12 December 2020

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

1 reference

12 December 2020

Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells.

1 reference

12 December 2020

Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

1 reference

12 December 2020

Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells

1 reference

12 December 2020

Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells

1 reference

12 December 2020

Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn

1 reference

12 December 2020

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

1 reference

12 December 2020

Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells

1 reference

12 December 2020

Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells

1 reference

12 December 2020

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

12 December 2020

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

12 December 2020

The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

1 reference

12 December 2020

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells

1 reference

12 December 2020

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

1 reference

12 December 2020

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

12 December 2020

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

1 reference

12 December 2020

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

12 December 2020

Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib

1 reference

12 December 2020

Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion

1 reference

12 December 2020

Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin

1 reference

12 December 2020

Regulation of survivin expression by IGF-1/mTOR signaling

1 reference

12 December 2020

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

1 reference

12 December 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

12 December 2020

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

12 December 2020

Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells

1 reference

12 December 2020

Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

12 December 2020

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

12 December 2020

Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity

1 reference

12 December 2020

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis

1 reference

12 December 2020

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells

1 reference

12 December 2020

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

12 December 2020

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

12 December 2020

Benign breast disease and breast cancer risk: morphology and beyond

1 reference

12 December 2020

Cellular actions of the insulin-like growth factor binding proteins

1 reference

12 December 2020

Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line

1 reference

12 December 2020

Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells

1 reference

12 December 2020

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

1 reference

12 December 2020

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

12 December 2020

Growth factor receptor interplay and resistance in cancer

1 reference

12 December 2020

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

12 December 2020

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

1 reference

12 December 2020

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling

1 reference

12 December 2020

Overview of tyrosine kinase inhibitors in clinical breast cancer.

1 reference

12 December 2020

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

1 reference

12 December 2020

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

12 December 2020

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

12 December 2020

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice

1 reference

12 December 2020

The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility.

1 reference

12 December 2020

Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells

1 reference

12 December 2020

Substrate competitive inhibitors of IGF-1 receptor kinase

1 reference

12 December 2020

A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

12 December 2020

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

1 reference

12 December 2020

Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay

1 reference

12 December 2020

The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway

1 reference

12 December 2020

Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2

1 reference

12 December 2020

Herceptin: mechanisms of action and resistance

1 reference

12 December 2020

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

12 December 2020

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

12 December 2020

Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

12 December 2020

ErbBs in mammary development

1 reference

12 December 2020

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association

1 reference

12 December 2020

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

12 December 2020

10.1007/S10911-008-9107-3

Identifiers

DOI

1 reference

19 August 2017

1 reference